
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp's revenue from the Healthcare Life Sciences segment, which constitutes 40% of total revenues, demonstrated growth, with a year-over-year increase of 2% in FQ4, and an anticipated growth rate of high-single to low-double digits for FQ1 driven by multiple program ramps and recovering customer demand. The Aerospace and Defense segment is expected to witness sequential growth due to program ramps in commercial air and defense, aligning with the company's broader goal of 9-12% revenue growth for fiscal year 2026. Overall, the expected earnings growth rate is projected to outpace revenue growth significantly, showcasing the company's effective strategic implementation and operational leverage.
Bears say
Plexus Corp has experienced a decline in gross margins, falling to 9.9% from 10.1%, which indicates potential challenges in cost management and pricing power within its competitive landscape. Additionally, revenue from the Aerospace & Defense segment showed a significant decrease of 6% both quarter-over-quarter and year-over-year, raising concerns about demand stability in critical market areas. The outlook for Industrial revenues in the upcoming quarter also suggests a downward trend due to seasonality and moderating demand, compounded by broader economic signals indicating potential global growth slowdowns and manufacturing disruptions.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares